MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$6,310,112
Unit: Dollar
Positive Cash Flow Breakdown
Issuance of series a convertible...
Accrued expenses
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
(gain) loss on extinguishment of...
Repayment of notes payable rela...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Interest expense
0
0
-
-
Due from related party
0
-1,027,920
-
-
Other current liabilities
0
0
0
0
Amortization of debt discount
0
1,583,890
5,998,239
2,021,209
Initial recognition of forward purchase agreement liability
-
-
-95,062
-
Issuance of commitment shares under eloc agreement
-
-
-275,000
-
Loss on extinguishment of debt
-
238,224
-
-
(gain) loss on extinguishment of debt
1,115,455
-
0
0
Change in fair value of derivative liabilities and convertible notes
-275
251,807
3,470,145
775,062
Interest capitalized
0
9,008
-
-
Inventory write-off
42,372
-
-
-
Stock-based compensation expense
144,094
13,406
0
0
Prepaid expenses
-
-
-
-363,768
Prepaid expenses and other current assets
119,809
835,047
-174,254
-
Inventories
-39,152
116,814
217,723
35,437
Accounts payable
127,589
-139,535
-46,526
-1,318,670
Accrued expenses
272,474
-316,955
781,667
280,780
Net loss
-1,268,142
-3,222,892
-4,707,734
-1,850,493
Net cash flows used in operating activities
-2,115,674
-3,038,522
-927,841
-1,103,809
Proceeds from reverse recapitalization
0
0
0
-1
Proceeds from issuance of convertible notes
0
0
0
7,250,000
Repayment of convertible notes
-
-
0
3,032,645
Repayment of subscription agreement loan
-
-
-
483,474
Transaction costs paid in connection with convertible notes
-
-
0
907,499
Proceeds from notes payable - related party
0
0
0
0
Issuance of series a convertible preferred stock
9,000,000
8,951,119
-
-
Deferred financing costs
75,000
-
-
-
Proceeds from debenture
0
2,000,000
-
-
Repayment of debenture
0
2,173,913
-
-
Repayment of notes payable related party
499,214
885,564
500,000
-19,466
Net cash flows provided by financing activities
8,425,786
7,891,642
-16,526
2,845,847
Net change in cash
-
4,853,120
-
-
Net increase in cash and cash equivalents
6,310,112
4,853,120
-944,367
1,742,038
Cash and cash equivalents, beginning of the period
5,857,024
1,003,904
1,948,271
3,633
Cash and cash equivalents, end of the period
12,167,136
5,857,024
1,003,904
1,948,271
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of series a
convertible preferred stock
$9,000,000
Net cash flows
provided by financing...
$8,425,786
Canceled cashflow
$574,214
Net increase in cash
and cash...
$6,310,112
(653.37%↑ Y/Y)
Canceled cashflow
$2,115,674
Repayment of notes payable
related party
$499,214
Deferred financing costs
$75,000
Accrued expenses
$272,474
(384.37%↑ Y/Y)
Stock-based compensation
expense
$144,094
Accounts payable
$127,589
(258.72%↑ Y/Y)
Inventory write-off
$42,372
Inventories
-$39,152
Change in fair value of
derivative liabilities and...
-$275
(99.90%↑ Y/Y)
Net cash flows used
in operating...
-$2,115,674
(-85.53%↓ Y/Y)
Canceled cashflow
$625,956
Net loss
-$1,268,142
(35.99%↑ Y/Y)
(gain) loss on
extinguishment of debt
$1,115,455
(406.35%↑ Y/Y)
something is missing
-$238,224
Prepaid expenses and
other current assets
$119,809
Buy us a coffee
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)